EMJ Neurology 14 [Supplement 1] . 2026

In this issue

New real-world evidence for efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP) presented at the AAN and PNS congresses in 2026 provides important insights to help neurologists navigate its use in daily clinical practice, tackling key practical questions such as selecting patients for treatment and successfully switching from current therapy.